M. Davidson

发表

Immunotherapy for oesophagogastric cancer

I. Chau, M. Davidson, 2016, Expert opinion on biological therapy.

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

D. Cunningham, E. Smyth, M. Davidson, 2016, OncoTargets and therapy.

Two large, global phase 3 trials have confirmed the efficacy of the vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab in the second-line treatment of advanced gastric cancer (GC) and gastro-

I. Chau, M. Davidson, 2016 .

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

M. Aresu, S. Chua, I. Chau, 2022, Current oncology.

Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends.

D. Cunningham, M. Davidson, N. Starling, 2018, Cancer treatment reviews.

Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients

D. Cunningham, I. Chau, E. Kalaitzaki, 2018, Clinical colorectal cancer.

Colorectal cancer trial endpoints: time for dynamic thinking?

I. Chau, M. Davidson, 2016, The Lancet. Oncology.

Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.

S. Popat, M. Davidson, W. Cui, 2022, European journal of cancer.

A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.

A. George, H. Mugalaasi, S. Popat, 2022, Lung cancer.

Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.

D. Cunningham, I. Chau, C. Peckitt, 2019, European journal of cancer.

Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial.

I. Chau, M. Davidson, 2016, Translational gastroenterology and hepatology.

Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials.

D. Cunningham, I. Chau, C. Peckitt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice

D. Cunningham, M. Davidson, 2017, Current Colorectal Cancer Reports.

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma

M. Gerlinger, D. Cunningham, I. Assiotis, 2019, Cancers.

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer

A. Ashworth, J. Reis-Filho, D. Cunningham, 2017, Gut.

Current and Future Therapies for Advanced Gastric Cancer.

M. Davidson, N. Starling, A. Okines, 2015, Clinical colorectal cancer.

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

Rajiv Kumar, T. Yap, M. O'Brien, 2016, Cancer Chemotherapy and Pharmacology.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

M. Gerlinger, M. Davies, B. Herman, 2018, Clinical chemistry.

Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches

I. Chau, M. Davidson, 2018, Expert review of anticancer therapy.

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

M. Davidson, N. Starling, 2016, OncoTargets and therapy.

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

A. Wotherspoon, D. Cunningham, C. Lord, 2019, European journal of cancer.

Ultra-sensitive mutation detection and genome-wide DNA copy 11 number reconstruction by error corrected circulating tumor DNA 12 sequencing 13 14

M. Davies, B. Herman, M. Hubank, 2018 .

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

I. Locke, S. Popat, M. Davidson, 2021, Journal of Thoracic Oncology.

Gastric Cancer - From Aetiology to Management: Differences Between the East and the West.

V. Lee, K. Lam, T. So, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

T. Hickish, D. Cunningham, I. Chau, 2017, World journal of gastrointestinal oncology.

642PSurvival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: Results from an analysis of over 500 patients (pts)

D. Cunningham, I. Chau, C. Peckitt, 2017 .

Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.

M. Gerlinger, D. Cunningham, Sacheen Kumar, 2021 .

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

I. Locke, P. Molyneaux, F. McDonald, 2021, Frontiers in Medicine.

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastroesophageal junction adenocarcinoma

E. Smyth, M. Davidson, D. Cunningham, 2016 .

Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.

S. Popat, M. Davidson, W. Cui, 2022, European journal of cancer.

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond

S. Popat, K. Joshi, M. Davidson, 2021, Lung Cancer.

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

D. Cunningham, M. Davidson, Elizabeth C. Smyth, 2016, OncoTargets and therapy.